ABSORPTION INTERACTIONS WITH FLUOROQUINOLONES - 1995 UPDATE

被引:68
作者
LOMAESTRO, BM
BAILIE, GR
机构
[1] Pharmacy Department, Albany Medical Center Hospital, Albany, New York
[2] Albany College of Pharmacy, Albany, New York
[3] Pharmacy Department (A-85), Cliniical Pharmacy Specialist, Albany Medical Center Hospital, Albany, New York, 12208, New Scotland Ave
关键词
D O I
10.2165/00002018-199512050-00004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The utility of the fluoroquinolone class of antibiotics is rapidly expanding due to their favourable pharmacokinetic profile and the continuing development of new compounds. These agents are often used for indications not successfully treated with other orally available antimicrobials in the past, or for 'step-down' therapy in patients originally treated with intravenous agents. As the usage of these agents expands for serious systemic infections, knowledge of absorptive interactions with fluoroquinolones becomes paramount. Fluoroquinolones are often utilised in dosages and against modestly susceptible pathogens which allow a narrow margin for acceptable decreases in bioavailability. Chelation interactions with multivalent cations can result in inactivation of the fluoroquinolone with ramifications in vitro and in vivo. Chelation interactions have been reported to occur in between 22 and 76% of patients prescribed fluoroquinolones. Concurrent administration of magnesium-aluminium antacids and sucralfate has the greatest effect on the bioavailability of quinolones followed by iron, calcium and zinc. Spacing doses of fluoroquinolones and interactants has been suggested as a method of ensuring adequate quinolone absorption, but this can make optimal administration of the cation interactant difficult, if not imposible.
引用
收藏
页码:314 / 333
页数:20
相关论文
共 149 条
[1]  
Neu H.C., Chemical evolution of the fluoroquinolone antimicrobial agents, Am J Med, 87, 6 C, pp. 2S-9S, (1989)
[2]  
Foster M.T., Clinical use of fluoroquinolones, Postgrad Med, 89, (1991)
[3]  
Chu D.T.W., Fernandes P.B., Structure-activity relationships of the fluoroquinolones, Antimicrob Agents Chemother, 33, (1989)
[4]  
Maxwell A., The molecular basis of quinolone action, J Antimicrob Chemother, 30, (1992)
[5]  
Sanders W.E., Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections, Rev Infect Dis, 10, (1988)
[6]  
Sanders W.E., Oral ofloxacin: a critical review of the new drug application, Clin Infect Dis, 14, (1992)
[7]  
Monk J.P., Campoli-Richards D.M., Ofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic uses, Drugs, 33, (1987)
[8]  
Campoli-Richards D.M., Monk J.P., Price A., Et al., Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use, Drugs, 35, pp. 373-447, (1988)
[9]  
LeBel M., Ciprofloxacin: chemistry, mechanisms of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions, Pharmacotherapy, 8, pp. 3-33, (1988)
[10]  
Wolfson J.S., Hooper D.C., Pharmacokinetics of quinolones: newer aspects, Eur J Clin Microbiol Infect Dis, 10, (1991)